A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis
Authors
Kim Papp (ORCID: https://orcid.org/0000-0001-9557-3642)
Katrin Nopora (ORCID: https://orcid.org/0000-0002-7097-9715)
A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis
Kim Papp, Katrin Nopora, Sigrid Balser, Piotr Rewerski et al.
Citations
1 citations
Journal
Advances in Therapy
Topics
Biosimilars and Bioanalytical Methods
Field-Weighted Citation Impact (FWCI)
0.80
article
A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis
Kim Papp, Katrin Nopora, Sigrid Balser, Piotr Rewerski, Michael Trieb, B Freudensprung
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Advances in TherapyVol. 42(5)
Institutions
University of Toronto (CA), Probity Medical Research (CA), Krakow Cardiovascular Research Institute (PL), Fraunhofer-Gesellschaft (DE)